- |||||||||| ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. (Pubmed Central) - Jul 18, 2020
It was also shown that serum derived from rats following LPV oral administration in two formulations and Kaletra significantly decreased the multiplication of HIV-1 in cultured SupT1 cells. Furthermore, the LPV formulations markedly restricted the titer of infectious HIV-1 production compared to Kaletra confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Serotonin syndrome in two COVID-19 patients treated with lopinavir/ritonavir. (Pubmed Central) - Jul 17, 2020
Furthermore, the LPV formulations markedly restricted the titer of infectious HIV-1 production compared to Kaletra confirming the improved antiviral activity of LPV delivered in the rat blood circulation by the nanocapsules embedded in microparticle formulations. No abstract available
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). (Pubmed Central) - Jul 17, 2020
Clinically available and investigational immunomodulators, such as the interleukin 6 inhibitors tocilizumab and sarilumab and the anti-granulocyte-macrophage colony-stimulating factor lenzilumab, are being tested for their anticipated effect in counteracting the pro-inflammatory cytokine environment that characterizes severe and critical COVID-19...The authors, therefore, encourage the enrollment of eligible patients to multiple ongoing clinical trials that assess the efficacy and safety of these candidate therapies. Until the results of controlled trials are available, none of the suggested therapeutics is clinically proven as an effective therapy for COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: Pharmacies on the Frontline: Responding to the COVID-19 Pandemic. (Pubmed Central) - Jul 17, 2020
The commercial lopinavir/ritonavir oral liquid is in short supply and may need to be compounded soon. We are all in this one together, from the essential workers to the children, and pharmacists are emerging as one of the first-line responders.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, PK/PD data, Review, Journal, Adverse drug reaction: Major Neurologic Adverse Drug Reactions, Potential Drug-Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review. (Pubmed Central) - Jul 17, 2020
In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).
- |||||||||| NN1213 / Novo Nordisk
Trial primary completion date: EIT: Early Infant HIV Treatment in Botswana (clinicaltrials.gov) - Jul 16, 2020
P2/3, N=75, Recruiting,
The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs). Trial primary completion date: Jul 2020 --> May 2021
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Clinical management of COVID-19. (Pubmed Central) - Jul 15, 2020
Among the currently available drugs, hydroxychloroquine and lopinavir/ritonavir may be considered for patients with severe COVID-19 infection, awaiting further clinical trials. Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Journal: BET 1: Lopinavir-ritonavir and COVID-19. (Pubmed Central) - Jul 15, 2020
Stringent droplet and contact precautions will protect healthcare workers against most clinical exposures to COVID-19. No abstract available
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Cardiovascular disease management during the coronavirus disease 2019 pandemic. (Pubmed Central) - Jul 15, 2020
In patients with elevated cardiac enzymes, it is very important to differentiate patients with Type 2 myocardial infarction or myocarditis from those with true acute coronary syndromes because invasive percutaneous intervention management in the former may be unnecessary, especially if they are hemodynamically stable. Finally, patients with baseline QT prolongation or those taking QT prolonging drugs must be cautious when treating with lopinavir/ritonavir and hydroxychloroquine for COVID-19.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. (Pubmed Central) - Jul 15, 2020
On the other hand, the use of steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) has been discouraged based on concerns about their adverse effects. Over the past two decades, coronaviruses have caused major epidemics and outbreaks worldwide, whilst modern medicine has been playing catch-up all along.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Review, Journal: Clinical Perspective on 2019 Novel Coronavirus Pneumonia: A Systematic Review of Published Case Reports. (Pubmed Central) - Jul 15, 2020
Nonetheless, we need more randomized clinical trials (RCTs) and treatment guidelines for developing effective management of the 2019-nCoV and improve patient outcomes by reducing mortality in high-risk patients. We also need more clinical trials and management guidelines for the effective management of 2019-nCoV pneumonia.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Systematic literature review on novel corona virus SARS-CoV-2: a threat to human era. (Pubmed Central) - Jul 15, 2020
(4) Researchers' claim that nutrition and immunity enhancers and treatment plans such as arbidol, lopinavir/ritonavir, convalescent plasma and mesenchymal stem cells and drugs including remdesivir, hydroxychloroquine, azithromycin and favipiravir are effective against COVID-19. This complied report serves as guide to help the administrators, researchers and the medical officers to adopt recommended intervention strategies and the optimal treatment/drug against COVID-19.
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, lopinavir/ritonavir / Generic mfg.
Clinical, PK/PD data, Journal: Population Pharmacokinetics of Pretomanid. (Pubmed Central) - Jul 8, 2020
HIV-positive subjects taking efavirenz and lopinavir/ritonavir had exposures that were reduced by 46% and 17%, respectively. There was little evidence for noteworthy effects of regimen partners on pretomanid.Standard diagnostics indicated that the model described the voluminous, diverse data well, so that the model could be used to generate exposure metrics for exposure/response analyses to be reported elsewhere.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives. (Pubmed Central) - Jul 8, 2020
The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy.
- |||||||||| Trial completion date, Trial primary completion date: RECOVERY: Randomised Evaluation of COVID-19 Therapy (clinicaltrials.gov) - Jul 6, 2020
P2/3, N=15000, Recruiting,
Assessment of severity was crucial to manage a large number of patients. Trial completion date: Jun 2021 --> Dec 2031 | Trial primary completion date: Dec 2020 --> Dec 2021
- |||||||||| lamivudine / Generic mfg., abacavir/lamivudine / Generic mfg., lopinavir/ritonavir / Generic mfg.
[VIRTUAL] Small Airway Disease and Brochodilator Response in Children with HIV in Sub Saharan Africa (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_7084;
The mean z scores for all acceptable spirometry were: %FEV/FVC 82%; FEV: pre BDR zFEV1 -2.27, postBDR zFEV1 -2.03; % change postBDR 4.28%; least changes in FVC: pre BDR zFVC -1,92 post BDR zFVC -1,88; % change post BDR 0.62%; with significant changes in FEF 25-75: pre BDR zFEF 25-75 -1.63; post BDR zFEF 25-75 -1,14; % change post BDR 21.07% CONCLUSIONS. Spirometric values of FEF 25-75 BDR is useful to diagnose SAD in children and helps identify children that require long term follow-up of their lung function.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. (Pubmed Central) - Jul 3, 2020
SARS-CoV-2 infection already affects a significant number of Spanish patients on RRT, mainly those on ICH, hospitalization rates are very high and mortality is high; age and the development of pneumonia are factors associated with mortality. No abstract available
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: Lessons Learned so Far from the Pandemic: A Review on Pregnants and Neonates with COVID-19. (Pubmed Central) - Jul 3, 2020
As ribavirin and favipiravir have teratogenic effects, there are some debates on the use of ribavirin in severe cases...Knowledge about neonatal outcomes of COVID-19 was based on studies of the last trimester of pregnancy. There is much to be learnt about COVID-19 in pregnant women and in the neonates, especially concerning prognosis- and treatment-related issues.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. (Pubmed Central) - Jul 3, 2020
Significant caution should be exercised if using any of the medications being trialled for the treatment of COVID-19 until robust clinical trial data are available. An even higher threshold of vigilance should be maintained for patients with pre-existing conditions and older adults due to added toxicity and drug interactions, especially with psychotropic agents.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Review, Journal: Emerging pharmacotherapies for COVID-19. (Pubmed Central) - Jul 1, 2020
Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.
- |||||||||| lopinavir/ritonavir / Generic mfg.
Review, Journal: COVID-19: Time for Post-Exposure Prophylaxis? (Pubmed Central) - Jul 1, 2020
Initial experiences with the use of hydroxychloroquine to prevent COVID-19 also seem promising. Post-exposure chemoprophylaxis might help mitigate the spread of SARS-CoV-2 in the current phase of the COVID-19 pandemic.
- |||||||||| ritonavir / Generic mfg., lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. (Pubmed Central) - Jul 1, 2020
P2
*Use of remdesivir as treatment for COVID-19 is permitted...A recent clinical trial evaluating the efficacy and safety of lopinavir- ritonavir for patients hospitalized with severe COVID-19 used a similar ordinal scale, as have recent clinical trials of novel therapeutics for severe influenza, including a post-hoc analysis of a trial evaluating immune plasma...ClinicalTrials.gov: NCT04359810 Date of trial registration: April 24, 2020 Retrospectively registered FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma, lopinavir/ritonavir / Generic mfg.
Clinical, Journal: Hospital Pharmacy Compounding against COVID-19 pandemic. (Pubmed Central) - Jul 1, 2020
In addition, the pandemic has revealed the scarcity of research on such basic aspects as agent stability and drug compatibility. One of the most relevant conclusions drawn from the COVID-19 pandemic is that the basic areas of hospital pharmacy, along with other, must be maintained and reinforced, as these are the areas that make us essential.
|
